$CYTK News

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise

Cytokinetics CEO on the launch of its first commercial drug

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced?

How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results

Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?

Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says

UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)